Investigating Adjuvant Chemo to Increase Survival for GI Tract G3 Neuroendocrine Tumors and Carcinomas
Introduction High-grade (G3) neuroendocrine tumors (NETs) are rare and extremely aggressive forms of cancer (citation). An estimated 8,000 NETs are diagnosed in the United States annually (citation). Of these estimated 8,000 cases, approximately 60% originate from the gastrointestinal (GI) tract (citation), and 20% of patients present with high-grade disease (citation) The incidence of NETs … Read more